Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic Constipation

• Status: Completed
• Trial end date: 2000-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether prucalopride is safe and effective in the re-treatment of chronic constipation.

Hypothesis:

Retreatment is as effective and safe as treatment with prucalopride in patients with chronic constipation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Movetis
• Treatments: Prucalopride

Criteria

Inclusion Criteria:

1. Male and non-pregnant, non-breast-feeding female outpatients at least 18 years of age (no upper age limit).

2. History of constipation; the patient reported having, on average, 2 or fewer spontaneous bowel movements per week that resulted in a feeling of complete evacuation as well as the occurrence of one or more of the following for at least 6 months before the selection visit:

• very hard (little balls) and/or hard stools at least a quarter of the stools;

• sensation of incomplete evacuation following at least a quarter of the stools;

• straining at defecation at least a quarter of the time. The above criteria were only applicable for spontaneous bowel movements, i.e. not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.

Patients who never had spontaneous bowel movements were considered to be constipated and were eligible for the study.

3. Having functional constipation. Constipation that was not induced by secondary causes of constipation (see exclusion criteria 1 through 7).

4. Willing and able to fill out his/her own diary and questionnaires without help, and able to read and write English.

5. Written informed consent, signed by the patient or legally acceptable representative and by the investigator.

6. Availability for follow-up during the study period as determined in the protocol.

Exclusion Criteria:

1. Patients in whom constipation was thought to be drug-induced, or who were using any disallowed medication

2. Patients with insulin-dependent diabetes mellitus.

3. Patients suffering from endocrine disorders.

4. Patients suffering from neurologic disorders

5. Presence of a megacolon/megarectum or a diagnosis of pseudo-obstruction.

6. Constipation as a result of surgery.

7. Known or suspected organic disorders of the large bowel (i.e. obstruction, carcinoma, or inflammatory bowel disease). Results of a barium enema with flexible sigmoidoscopy or of a colonoscopic examination performed within the last 12 months were needed to rule out organic disorders. A colonoscopic examination or barium enema with flexible sigmoidoscopy performed within the last 3 years was acceptable if the examination was performed for an evaluation of constipation, and there was no history or evidence of weight loss, anaemia, or rectal bleeding, and the patient had 3 consecutively negative stool occult blood tests at screening. Patients with polyps discovered by colonoscopy that were untreated (i.e. by polypectomy) were to be excluded.

8. Presence of known serious, uncontrolled illnesses: clinically significant cardiac, vascular, pulmonary, endocrine, psychiatric disorders (including active alcohol or drug abuse) or metabolic disturbances.

9. Clinically significant cancer within the past 5 years.

10. Subjects known to be HIV positive.

11. Impaired renal function, i.e. serum creatinine concentration >2 mg/dL (>180 micromol/L) or creatinine clearance ≤50 mL/min.

12. Clinically significant abnormalities of haematology, urinalysis, or blood chemistry.

13. Females of child-bearing potential without adequate contraceptive protection during the study. Oral contraceptives, Depo Provera® and Norplant® had to be used for at least 3 months prior to randomisation. Intrauterine devices (IUDs), sterilization, or a double barrier method were other acceptable methods of birth control.

14. Treatment with an investigational drug in the 30 days preceding the run-in phase of the study.

15. Previous treatment with either prucalopride formulation.